Retrophin (RTRX) PT Raised to $40 at BMO Capital
Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.
BMO Capital analyst Do Kim reiterated an Outperform rating and boosted his price target on Retrophin (NASDAQ: RTRX) to $40.00 (from $28.00) and increase the probability of success for Sparsentan to 45% from 25%, following positive Phase II DUET data.
Kim commented, "While we model an accelerated approval for Sparsentan, we recognize the increased risk regarding an early filing, given little visibility on the likely commercial dose. Our 45% risk adjustment reflects the potential need for a confirmatory Phase III trial prior to regulatory filing."
Shares of Retrophin closed at $16.32 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BMO Capital Raises Price Target on IHS Markit (INFO) Following 4Q
- Neurocrine Bio. (NBIX) PT Lowered to $56 at Jefferies Amid Adult Tourette's Data
- Target (TGT) PT, Estimates Cut at Buckingham Research Following Miss
Create E-mail Alert Related CategoriesAnalyst Comments, Analyst PT Change
Related EntitiesBMO Capital
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!